BioNTech (BNTX) Stock Forecast & Price Target

$111.93 -0.83 (-0.74%)

As of 01/17/2025 04:00 PM Eastern

BioNTech - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 17 Analyst Ratings

Sell
0

Hold
3

Buy
14

Based on 17 Wall Street analysts who have issued ratings for BioNTech in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 17 analysts, 3 have given a hold rating, 13 have given a buy rating, and 1 has given a strong buy rating for BNTX.

Consensus Price Target

$142.72
27.50% Upside

According to the 17 analysts' twelve-month price targets for BioNTech, the average price target is $142.72. The highest price target for BNTX is $172.00, while the lowest price target for BNTX is $122.00. The average price target represents a forecasted upside of 27.50% from the current price of $111.93.

Get the Latest News and Ratings for BNTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BioNTech and its competitors.

BNTX Analyst Ratings Over Time

Type	Current Forecast 1/21/24 to 1/20/25	1 Month Ago 12/22/23 to 12/21/24	3 Months Ago 10/23/23 to 10/22/24	1 Year Ago 1/21/23 to 1/21/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	12 Buy rating(s)	8 Buy rating(s)	4 Buy rating(s)
Hold	3 Hold rating(s)	4 Hold rating(s)	5 Hold rating(s)	6 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$142.72	$140.76	$135.54	$151.46
Forecasted Upside	27.50% Upside	24.48% Upside	22.24% Upside	54.21% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

BNTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BNTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

BioNTech Stock vs. The Competition

Type	BioNTech	Medical Companies	S&P 500
Consensus Rating Score	2.88	2.82	2.52
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	27.50% Upside	24,741.16% Upside	12.44% Upside
News Sentiment Rating	Neutral News See Recent BNTX News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
1/10/2025	Truist Financial 2 of 5 stars		Initiated Coverage	Buy	$172.00	+40.81%
12/11/2024	Wells Fargo & Company 3 of 5 stars	M. Bansal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$170.00	+45.49%
12/2/2024	BMO Capital Markets 4 of 5 stars		Reiterated Rating	Outperform
11/27/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$171.00 ➝ $171.44	+44.63%
11/26/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$124.00 ➝ $122.00	+1.03%
11/19/2024	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	H. Gillis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$130.00	+27.61%
11/19/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Kasimov Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	In-Line ➝ Outperform	$110.00 ➝ $125.00	+22.71%
11/18/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$150.00 ➝ $150.00	+50.42%
11/8/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Shibutani Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$90.00 ➝ $137.00	+26.99%
11/5/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$132.00 ➝ $122.00	+10.28%
Get the Latest News and Ratings for BNTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.
10/7/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$97.00 ➝ $136.00	+10.88%
9/24/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight	$93.00 ➝ $145.00	+28.26%
9/19/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$95.00 ➝ $150.00	+33.87%
9/18/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$97.00 ➝ $131.00	+5.04%
9/17/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$96.00 ➝ $150.00	+21.49%
9/16/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$125.00 ➝ $150.00	+23.75%
8/2/2024	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Kumar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
1/5/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform
5/17/2023	Redburn Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$165.00 ➝ $170.00	+60.98%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 07:49 PM ET.

Should I Buy BioNTech Stock? BNTX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, January 20, 2025. Please send any questions or comments about these BioNTech pros and cons to contact@marketbeat.com.

BioNTech
Bull Case

Here are some ways that investors could benefit from investing in BioNTech SE:

BioNTech SE reported a significant earnings per share (EPS) of $0.81 for the latest quarter, surpassing analysts' expectations of a loss of $1.26 by $2.07. This strong performance indicates the company's ability to generate profits, which can be attractive to investors.
The company achieved a remarkable revenue of $1.24 billion during the quarter, significantly exceeding the forecast of $514.08 million. This substantial revenue growth of 38.9% year-over-year demonstrates BioNTech's expanding market presence and product demand.
Recent institutional investments show strong confidence in BioNTech SE, with FMR LLC increasing its stake by 797.8%, indicating that large investors see potential for growth and profitability.
BioNTech SE is actively involved in developing immunotherapies for cancer and infectious diseases, positioning itself in a high-demand sector with significant growth potential as healthcare continues to evolve.
The current stock price of BioNTech SE reflects its recent performance and market sentiment, making it a potentially attractive entry point for investors looking to capitalize on its growth trajectory.

BioNTech
Bear Case

Investors should be bearish about investing in BioNTech SE for these reasons:

Despite the positive EPS, BioNTech SE has a negative net margin of 15.16%, indicating that the company is currently spending more than it earns, which could be a concern for long-term profitability.
The company also has a negative return on equity (ROE) of 2.35%, suggesting that it is not effectively generating profits from its equity investments, which may deter some investors.
Analysts project that BioNTech SE will post a negative EPS of -3.72 for the current year, indicating potential challenges ahead that could impact investor confidence.
While institutional interest is high, the overall ownership by institutional investors stands at only 15.52%, which may suggest limited confidence from larger investment entities in the company's long-term prospects.
The biotechnology sector can be highly volatile and subject to regulatory changes, which may pose risks to BioNTech SE's operations and stock performance, making it a riskier investment choice.

BNTX Forecast - Frequently Asked Questions

: According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for BioNTech is $142.72, with a high forecast of $172.00 and a low forecast of $122.00.
: 17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 3 hold ratings, 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BNTX shares.
: According to analysts, BioNTech's stock has a predicted upside of 27.50% based on their 12-month stock forecasts.
: Over the previous 90 days, BioNTech's stock had 2 upgrades by analysts.
: BioNTech has been rated by research analysts at Berenberg Bank, BMO Capital Markets, Canaccord Genuity Group, Evercore ISI, HC Wainwright, JPMorgan Chase & Co., TD Cowen, The Goldman Sachs Group, Truist Financial, and Wells Fargo & Company in the past 90 days.
: Analysts like BioNTech more than other "medical" companies. The consensus rating score for BioNTech is 2.88 while the average consensus rating score for "medical" companies is 2.82. Learn more on how BNTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This page (NASDAQ:BNTX) was last updated on 1/20/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioNTech (BNTX) Stock Forecast & Price Target